Argos Therapeutics, Inc.

P11

Argos Therapeutics, Inc. is developing breakthrough immunotherapies that target unique features of a patient’s disease. This new generation of personalized cancer and infectious disease therapeutics trains the immune system to recognize and attack the disease. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases.


Argos, a private biotechnology company, is headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.

Persons:

• Charles Nicolette
  Scientific responsible

     [ RDF ]   [ RelFinder ]

• Phone: +1 (919) 287-6300
• http://www.argostherapeutics.com/

• 4233 Technology Drive
  Durham (North Carolina)
  USA